ZD6474 Coerces Breast Cancer for an Apoptotic Journey

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2010 Feb 18

PMID 20160495

Authors

Binoj C Nair

Ratna K Vadlamudi

Affiliations

Soon will be listed here.

References

Guidi A, Schnitt S, Fischer L, Tognazzi K, Harris J, Dvorak H . Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer. 1997; 80(10):1945-53. DOI: 10.1002/(sici)1097-0142(19971115)80:10<1945::aid-cncr11>3.0.co;2-y. View

Kushlinskii N, Gershtein E . Role of vascular endothelial growth factor during breast cancer. Bull Exp Biol Med. 2002; 133(6):521-8. DOI: 10.1023/a:1020259702427. View

Hackel P, Zwick E, Prenzel N, Ullrich A . Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol. 1999; 11(2):184-9. DOI: 10.1016/s0955-0674(99)80024-6. View

Rimawi M, Shetty P, Weiss H, Schiff R, Osborne C, Chamness G . Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer. 2010; 116(5):1234-42. PMC: 2829330. DOI: 10.1002/cncr.24816. View

Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11):1160-74. DOI: 10.1056/NEJMra0707704. View

Agrawal A, Gutteridge E, Gee J, Nicholson R, Robertson J . Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 2005; 12 Suppl 1:S135-44. DOI: 10.1677/erc.1.01059. View

Tortora G, Ciardiello F, Gasparini G . Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol. 2008; 5(9):521-30. DOI: 10.1038/ncponc1161. View

Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R . ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007; 117(8):2051-8. PMC: 1934579. DOI: 10.1172/JCI32278. View

Saltz L, Easley C, Kirkpatrick P . Panitumumab. Nat Rev Drug Discov. 2007; 5(12):987-8. DOI: 10.1038/nrd2204. View

10.

Valachis A, Polyzos N, Patsopoulos N, Georgoulias V, Mavroudis D, Mauri D . Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010; 122(1):1-7. DOI: 10.1007/s10549-009-0727-0. View

11.

Arteaga C, Moulder S, Yakes F . HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol. 2002; 29(3 Suppl 11):4-10. DOI: 10.1053/sonc.2002.34047. View

12.

Levin E . Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 2003; 17(3):309-17. DOI: 10.1210/me.2002-0368. View

13.

Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu Q . Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer. 2007; 121(9):2095-2104. DOI: 10.1002/ijc.22955. View

14.

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

15.

Flynn J, Wong C, Wu J . Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer. J Oncol. 2009; 2009:526963. PMC: 2668926. DOI: 10.1155/2009/526963. View

16.

Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher P, Mandal M . ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther. 2010; 9(8):592-603. DOI: 10.4161/cbt.9.8.11103. View

17.

Morabito A, Piccirillo M, Falasconi F, De Feo G, Del Giudice A, Bryce J . Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009; 14(4):378-90. DOI: 10.1634/theoncologist.2008-0261. View